About Professor Markus Seibel

Markus Seibel has passion for basic and clinical research into the many aspects of bone health and biology and is an internationally recognised researcher in the field of bone metabolism.

Markus’ major scientific achievements are in the area of bone physiology and pathophysiology. Together with his team at the ANZAC Research Institute he made ground-breaking discoveries regarding the role of steroid hormones (and in particular glucocorticoids) in bone and systemic fuel metabolism. The team’s research has added significantly to our understanding how bone cells, via steroid hormone action, interact with tissues involved in energy utilisation. For example, we now know that glucocorticoid-induced diabetes is really a bone disease – a concept still somewhat novel but increasingly supported by evidence. Markus’ other basic research interests include the biology of cancer metastases to bone, and the development of novel markers of bone metabolism.

In terms of translational and clinical research, Markus has been a national and international leader in the development, validation and promotion of secondary fracture prevention programs. These clinical pathways aim to reduce the risk of further fracture in people who have suffered an initial fragility (osteoporotic) fracture. The significance of these programs lies in the fact that in Australia, only 20-30% of people who have experienced an osteoporotic fracture are receiving effective therapy. This is despite the availability of highly effective treatments for osteoporosis. In other clinical research, Markus is a CI of the Concord-based CHAMP study, which investigates clinically relevant aspects of ageing in men, including osteoporosis and falls.

Markus received his scientific and medical training in Germany, Switzerland and in the US. From 1991-2001, he was the Director of the Bone Research Laboratory at the University of Heidelberg, Germany. During this time, he supervised 19 MD and PhD students and held grants from both national and international funding bodies. He served as President of the German Academy of Bone & Joint Sciences (2000-2001), as chairman of the ASBMR working group on Biomarkers of Bone Turnover (1996-2003), and as a member of the Board of Directors, Roof Association of the German Bone Research Societies (1998-2001). In November 2001, he took up the position of Professor of Endocrinology at the University of Sydney, and became the inaugural Director of the Bone Research Program at ANZAC Research Institute (www.anzac.edu.au). He also heads the Department of Endocrinology and Metabolism at Concord Hospital (www.slhd.nsw.gov.au/Concord/Endocrinology_about.html). In 2016, Markus founded the SOS Fracture Alliance (www.sosfracturealliance.org.au), which by now has over 3 million individual members and promotes the nation-wide implementation of secondary fracture prevention services.

In 2017, Markus was elected a Fellow of the Australian Academy of Health and Medical Sciences.

Selected publications

For a comprehensive list of Professor Seibel's publicatons, please visit his Sydney Medical School profile page.